Storys zum Thema Health

Merck Healthcare Germany

ERBITUX® Approved for First-line Use in China in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Darmstadt, Germany (ots/PRNewswire) - Approval is for ERBITUX® in combination with platinum-based therapy with fluorouracil for the first-line treatment of R/M SCCHN Pivotal Phase III study shows significant improvements with ERBITUX® in combination with platinum-based therapy with fluorouracil in response rate, ...

Sophia Genetics

SOPHiA GENETICS' Board of Directors Elects Troy Cox as New Chairman

Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that former Foundation Medicine CEO Troy Cox has been elected as Chairman of the Board of Directors, effective March 1, 2020. He is replacing Antoine Duchateau, who has served as chairman since 2013 and will continue as a board member. Cox joined the ...

Norgine GmbH

New Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease

Amsterdam (ots/PRNewswire) - - Ferric maltol (FM) was associated with substantially lower use of healthcare resources than IV ferric carboxymaltose (FCM) - IV FCMwas linked to greater productivity loss and disruption to patients' work and family life due to the need for clinic-based IV administration - 50% of ...

MSD Merck Sharp & Dohme AG

MSD in Switzerland launches new gender-neutral parental leave policy effective February 1st, 2020

Lucerne (ots) - Following its nomination for an eight time in a row as Top Employer Switzerland, MSD (Merck Sharp & Dohme AG) is delighted to announce the introduction of a new gender-neutral parental leave policy to all its employees within ...

Norgine GmbH

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe

Amsterdam (ots/PRNewswire) - - Norgine to receive upfront payments, undisclosed milestone payments along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries Norgine B.V. (Norgine), a leading European specialist pharmaceutical company, today ...

Performance BioFilaments Inc

Performance BioFilaments Reaches New Milestone in Nanofibrillated Cellulose Commercial Production

Vancouver (ots/PRNewswire) - - Performance BioFilaments Inc. is pleased to announce the availability of high performance nanofibrillated cellulose (NFC) starting in 2021. The construction of a 21 metric tons per day plant, located at Resolute's Kénogami paper mill in Quebec, will ensure a reliable commercial supply of NFC. This wood-derived biomaterial can ...

Smart Medical Systems Ltd

SMART Medical Systems Launches its G-EYE® 760R Colonoscope in the European Endoscopy Market Through FUJIFILM Europe, Under Strategic Distribution Partnership With FUJIFILM Corporation, to Provide Synergetic Colonoscopy Solution in Fight Against Colon ...

Ra'anana, Israel (ots/PRNewswire) - SMART's G-EYE® 760R colonoscope, incorporating its G-EYE® Balloon Technology designed to increase the detection of cancerous polyps in colonoscopy, will become available by FUJIFILM Europe with its state-of-the-art ELUXEO system, as part of the newly formed strategic ...

MSD Merck Sharp & Dohme AG

On World Cancer Day, MSD Switzerland Stands United in Support of its Patients

Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...

MSD Merck Sharp & Dohme AG

MSD Expands Operations in Switzerland

Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...

Abcam plc

Transaction adds comprehensive gene editing capabilities and engine to drive expansion of Abcam's 'off-the-shelf' edited cell line portfolio

Cambridge, England and Milpitas, California (ots/PRNewswire) - Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce the asset purchase of the gene editing platform and oncology product portfolio of Applied StemCell, Inc. (ASC) for life science research and diagnostic ...

Hamamatsu Photonics Europe GmbH

Hamamatsu Photonics has Developed a Palm-sized FTIR Engine Capable of Highly Sensitive Detection of Near-infrared Light at Wavelengths Ranging From 1.1 to 2.5 Micrometers

Hamamatsu City, Japan (ots/PRNewswire) - By applying its own unique microelectro-mechanical systems (MEMS) technology, Hamamatsu Photonics has successfully developed a palm-sized "Fourier transform infrared spectrometer (FTIR) engine C15511-01" offering high sensitivity to near-infrared light at wavelengths from 1.1 ...

ZENTIVA Pharma GmbH

Zentiva Celebrates The Parc's Impressive Scientific Track Record in 2019

Prague (ots/PRNewswire) - Zentiva welcomed The Pharmaceutical Applied Research Center (The Parc) to their Prague headquarters to celebrate the first anniversary of The Parc Awards. The Parc is a unique research platform designed to prepare future generations of pharmaceutical scientists and engineers. Twenty-nine students are currently included in the program and an ...

Helsana Gruppe

Claudine Blaser Egger to become a new member of the Helsana Executive Board

MSD Merck Sharp & Dohme AG

Swissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)

Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...

COMPASS Pathways

COMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's ...

Senzer Limited

Senzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry

London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be used in Europe's first and biggest national medical cannabis registry, Project TWENTY21, in which an expected 20,000 patients will be enrolled by the end of 2021 creating the largest body of evidence for the efficacy of medical cannabis. Drug Science, the leading independent scientific body on ...

Kyowa Kirin International PLC

Kyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency

Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...

Abcam plc

Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability

Cambridge, England (ots/PRNewswire) - - Includes leading protein conjugation technologies and industry brands Lightning-Link® and CaptSure(TM) - Opportunity to combine Expedeon and Abcam's technologies to create new products to support research and diagnostic development Abcam plc, a global innovator in life ...

Daiichi Sankyo Europe GmbH

Large Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities

Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy (https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz070/5644339?redirectedFrom=fulltext), showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 ...

Canopy Growth Corporation

Canopy Growth Introduces First & Free - A Line of Branded Hemp-Derived CBD Products to the U.S. Market

Denver, Colorado (ots/PRNewswire) - Canopy Growth's first line of CBD products are available for purchase through e-commerce platform available at www.firstandfree.com - Canopy Growth Corporation, USA, LLC (TSX: WEED) (NYSE: CGC) ("Canopy Growth" or the "Company") today announced the launch of First & Free - a ...

COMPASS Pathways

COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers

London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...

Carl Zeiss AG

Tenth Record-Breaking Year in a Row for ZEISS

Stuttgart, Germany (ots/PRNewswire) - Revenue increases by 11 percent to 6.4 billion euros - EBIT exceeds 1 billion euros for the first time - All four segments contributed to growth - Medical technology and industrial and research solutions ensure above-average growth for the ZEISS Group - Semiconductor Manufacturing Technology sees strong growth with new EUV technology - ZEISS CEO Michael Kaschke: "As a global ...

Grünenthal Group

Jan Adams Appointed Chief Scientific Officer for Grünenthal

Aachen, Germany (ots/PRNewswire) - Grünenthal announced today that Jan Adams, MD has been appointed Chief Scientific Officer (CSO) and Member of the Corporate Executive Board effective 1 January 2020. Since July 2019, Jan has already served as acting CSO, leading the strategic re-alignment of Grünenthal's R&D organisation. Jan brings over 15 years of experience in healthcare and the biopharmaceutical industry. He joined ...

UCB Pharma

UCB Presents Final Results from Phase II Study of Rozanolixizumab in Primary Immune Thrombocytopenia (ITP) at 2019 ASH Annual Meeting

Brussels (ots/PRNewswire) - - Phase II data demonstrate that rozanolixizumab was well tolerated by patients with primary ITP across all dose groups - Clinically relevant improvements in platelet count and decrease in immunoglobin G (IgG) levels were observed in all dose groups - Safety, tolerability and efficacy ...